Legend Biotech announced that its investigational CAR-T therapy LB2501 achieved a 100% objective response rate and 83.3% complete response rate at the higher dose in a Phase 1 trial for relapsed or refractory B-cell non-Hodgkin lymphoma. The single infusion treatment generated CAR-T cells in vivo without lymphodepletion and showed a favorable safety profile, with no serious adverse events or deaths reported. These promising early results support further development of LB2501 as a novel, simplified CAR-T therapy that could improve treatment access for patients with limited options.
Celldex Therapeutics presented long-term Phase 2 results showing barzolvolimab provides rapid, significant, and durable relief from angioedema in patients with moderate to severe chronic spontaneous urticaria (CSU) refractory to antihistamines. Impre...
On World Blood Donor Day, June 14, 2026, more than 100 organizations in the US united to thank the 8 million annual blood donors and encourage more eligible people to donate. Blood donations are critical as a transfusion is needed every two seconds i...
Verizon and AT&T are both undergoing aggressive fiber network expansions but show different stock performances. Verizon trades near its 52-week high with improved earnings guidance and positive subscriber growth, while AT&T faces a recent downgrade a...
Hanwha Life Esports (HLE) is set to compete in the 2026 Mid-Season Invitational (MSI) with three players—Zeus, Zeka, and Viper—who have all participated in every major Riot Games international tournament. HLE secured the top seed from South Korea's L...
Strategy's executive chairman Michael Saylor announced another Bitcoin purchase set for Monday, adding to the company's nearly 850,000 BTC holdings valued at about $64 billion. The company has been buying Bitcoin at twice the rate of miner production...
